OverviewSuggest Edit

Daiichi Sankyo (第一三共株式会社) is a developer of pharmaceutical products. It engages in 4 businesses: the Innovative Pharmaceutical Business, the Generic Business, the Vaccine business, and the OTC-related business. The Innovative Pharmaceutical Business delivers a range of pharmaceuticals to patients ranging from the anticoagulant LIXIANA and other products in the primary care area to oncology products, among others, in the specialty care area. The Generic Business offers authorized generics (AG), or a new standard for generics featuring formulation, labelling, and packaging innovations that are easy to swallow but hard to swallow accidentally. The Vaccine business specializes in vaccines to prevent infectious diseases and develops a 3-valent combination vaccine containing three live attenuated viruses of measles, mumps, and rubella (MMR vaccine). The OTC-related business offers OTC drugs and a range of products including skincare cosmetics and oral care products.
TypePublic
Founded2005
HQTokyo, JP
Websitedaiichisankyo.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Mar 2021)16,033(+5%)
Job Openings517
Revenue (FY, 2021)¥962.5 B(-1%)
Share Price (May 2022)¥3.2 K
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Daiichi Sankyo

Sunao Manabe

Sunao Manabe

President and CEO
Satoru Kimura

Satoru Kimura

Head of Japan Business Unit
Masahiko Ohtsuki

Masahiko Ohtsuki

Head of Digital Transformation Management Div.
Shoji Hirashima

Shoji Hirashima

Head of Corporate Strategy Div.
Hiroyuki Okuzawa

Hiroyuki Okuzawa

Head of Corporate Planning & Management Div., CFO
Hironobu Furuta

Hironobu Furuta

Head of Corporate Affairs Div.
Show more

Daiichi Sankyo Office Locations

Daiichi Sankyo has offices in Tokyo, Chiba, Chiyoda, Chuo City and in 39 other locations
Tokyo, JP (HQ)
3-5-1, Nihonbashi, Honcho, Chuo-ku
Chiba, JP
2-6-1, Nakase, Mihama-ku
Chiyoda, JP
2716-1, Aza Kurakake, Oaza Akaiwa
Chuo City, JP
Nihonbashi Building, 3-14-10, Nihonbashi, Chuo-ku
Fukuoka, JP
2-10-1, Hakata Eki Higashi, Hakata
Hiratsuka, JP
1-12-1, Shinomiya
Show all (47)

Daiichi Sankyo Financials and Metrics

Daiichi Sankyo Revenue

Daiichi Sankyo's revenue was reported to be ¥962.52 b in FY, 2021
JPY

Revenue (Q3, 2022)

281.0b

Gross profit (Q3, 2022)

203.3b

Net income (Q3, 2022)

31.9b

EBITDA (Q3, 2022)

53.3b

EBIT (Q3, 2022)

39.1b

Market capitalization (12-May-2022)

5.7t

Closing stock price (12-May-2022)

3.2k

Cash (31-Dec-2021)

577.3b

EV

5.3t
Daiichi Sankyo's current market capitalization is ¥5.7 t.
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

960.2b929.7b981.8b962.5b

Cost of goods sold

(299.3b)(318.4b)(290.6b)(280.9b)

Gross profit

660.9b611.3b691.2b681.6b

R&D expense

(236.0b)(203.7b)(197.5b)(227.4b)
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Revenue

225.7b221.1b256.2b249.2b230.3b277.5b236.9b243.2b258.6b264.1b265.9b281.0b

Cost of goods sold

(73.5b)(70.5b)(86.6b)(75.0b)(75.8b)(66.4b)(68.1b)(72.0b)(73.4b)(70.5b)(73.1b)(77.7b)

Gross profit

152.2b150.6b169.7b174.3b154.6b211.1b168.9b171.2b185.2b193.6b192.8b203.3b

R&D expense

(45.5b)(48.2b)(48.9b)(41.2b)(44.7b)(51.1b)(48.8b)(55.7b)(59.1b)(54.0b)(55.0b)(60.1b)
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Cash

258.2b154.9b280.4b294.8b

Accounts Receivable

210.8b360.4b282.5b201.0b

Inventories

172.6b176.1b173.4b200.9b
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Cash

294.0b236.9b239.2b260.9b297.6b326.4b382.1b451.3b520.1b352.3b550.1b577.3b

Accounts Receivable

230.1b270.8b305.7b356.8b342.5b351.9b243.9b252.8b263.4b258.1b276.5b282.9b

Inventories

184.1b186.6b177.6b186.0b177.4b172.7b183.7b183.3b183.9b211.8b210.0b211.6b
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

81.0b85.8b141.2b74.1b

Depreciation and Amortization

46.7b46.2b52.6b57.4b

Inventories

(19.4b)(4.0b)(7.4b)(21.2b)

Accounts Payable

238.0m60.4b(44.7b)23.9b
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Net Income

29.6b58.6b98.0b57.1b87.0b160.0b41.4b67.0b99.6b47.1b86.0b125.9b

Depreciation and Amortization

11.2b22.6b34.3b12.9b26.4b39.2b14.1b28.5b42.9b14.7b29.0b43.2b

Inventories

(11.1b)(12.1b)(5.0b)(12.5b)(11.7b)(4.9b)(10.4b)(10.2b)(11.2b)(10.1b)(7.7b)(6.0b)

Accounts Payable

(27.4b)3.8b8.2b(23.9b)(59.0b)(85.5b)(30.3b)(22.0b)(19.1b)(33.9b)(33.0b)(23.4b)
JPYFY, 2018

Revenue/Employee

66.5m
Show all financial metrics

Daiichi Sankyo Operating Metrics

FY, 2019Dec, 2020

Phase I Trials Products

16

Phase II Trials Products

7

Phase III Trials Products

7

Trademarks

116
Show all operating metrics

Daiichi Sankyo Acquisitions / Subsidiaries

Company NameDateDeal Size
Im CoOctober 08, 2015
Rice ForceOctober 08, 2015
Ambit BiosciencesSeptember 29, 2014$410 m
Plexxikon Inc.April 04, 2011$935 m
Ranbaxy LaboratoriesNovember 30, 2008$4.6 b
U3 Pharma AGMay 26, 2008
Ambit Biosciences Corp.
American Regent, Inc.
Daiichi Sankyo
Daiichi Sankyo Biotech Co., Ltd.
Show more

Daiichi Sankyo Revenue Breakdown

Embed Graph

Daiichi Sankyo revenue breakdown by business segment: 92.8% from PHARMACEUTICAL DIVERSIFIED, 7.0% from HEALTHCARE and 0.2% from Other

Show all human capital metrics

Daiichi Sankyo Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Daiichi Sankyo Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Daiichi Sankyo Online and Social Media Presence

Embed Graph

Daiichi Sankyo News and Updates

$81 Billion Worldwide Musculoskeletal Disorders Drugs Industry to 2030 - Featuring Pfizer, Abbott Laboratories and Daiichi Sankyo Among Others

Dublin, May 10, 2021 (GLOBE NEWSWIRE) -- The "Musculoskeletal Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information…

Global Influenza Vaccines Market Report 2021-2027 Featuring Emerging Players - Moderna, Novavax, Daiichi Sankyo, & Versatope Therapeutics

DUBLIN, May 7, 2021 /PRNewswire/ -- The "Global Influenza Vaccines Market 2021 - 2027" report has been added to ResearchAndMarkets.com's offering. The number of people being vaccinated with influenza vaccines worldwide will reach 500 million by the year-end of 2027. The Report Analyses...

Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories

–  Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments ––  Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1 Billion ––  Demonstrates Daiichi Sankyo Group’s Commitment to the Bempedoic Acid Franchise and Strength of Existing Partnership –…

Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal

DUBLIN, April 14, 2021 /PRNewswire/ -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow,...

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for …

Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes Related to Additional Indication for the Antiplatelet Agent, Prasugrel Hydrochloride

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that a supplemental application for the antiplatelet agent, prasugrel hydrochloride (hereafter, prasugrel), was filed in Japan to expand the indication for prevention of recurrence of ischemic stroke as a partial change in i…
Show more

Daiichi Sankyo Frequently Asked Questions

  • When was Daiichi Sankyo founded?

    Daiichi Sankyo was founded in 2005.

  • Who are Daiichi Sankyo key executives?

    Daiichi Sankyo's key executives are Sunao Manabe, Satoru Kimura and Masahiko Ohtsuki.

  • How many employees does Daiichi Sankyo have?

    Daiichi Sankyo has 16,033 employees.

  • What is Daiichi Sankyo revenue?

    Latest Daiichi Sankyo annual revenue is ¥962.5 b.

  • What is Daiichi Sankyo revenue per employee?

    Latest Daiichi Sankyo revenue per employee is ¥60 m.

  • Who are Daiichi Sankyo competitors?

    Competitors of Daiichi Sankyo include Bayer, Bristol-Myers Squibb and Boehringer Ingelheim.

  • Where is Daiichi Sankyo headquarters?

    Daiichi Sankyo headquarters is located at 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo.

  • Where are Daiichi Sankyo offices?

    Daiichi Sankyo has offices in Tokyo, Chiba, Chiyoda, Chuo City and in 39 other locations.

  • How many offices does Daiichi Sankyo have?

    Daiichi Sankyo has 47 offices.